Tommy Fu

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag et al. · Blood · 2011 · 480 citations · Full text

Medicine, Hematology, Pharmacology +14

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

André Goy, Rajni Sinha, Michael E. Williams et al. · Journal of Clinical Oncology · 2013 · 349 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

Donna Reece, Kevin Song, Tommy Fu et al. · Blood · 2009 · 184 citations

Medicine, Oncology, Pharmacotherapy +15

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

Leonie Saft, Masoud Karimi, Mehran Ghaderi et al. · Haematologica · 2014 · 136 citations · Full text

Medicine, Hematology, Oncology +17

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials

Qian Shi, Christopher R. Flowers, Wolfgang Hiddemann et al. · Journal of Clinical Oncology · 2017 · 115 citations · Full text

Medicine, Oncology, Cancer Control +13